| 000 | 02798cam a2200301 4500500 | ||
|---|---|---|---|
| 005 | 20250121154512.0 | ||
| 041 | _afre | ||
| 042 | _adc | ||
| 100 | 1 | 0 |
_aLiang, Lin _eauthor |
| 700 | 1 | 0 |
_a Zhang, Ya-Mei _eauthor |
| 700 | 1 | 0 |
_a Chen, He _eauthor |
| 700 | 1 | 0 |
_a Ye, Li-Fang _eauthor |
| 700 | 1 | 0 |
_a Li, Shan-Shan _eauthor |
| 700 | 1 | 0 |
_a Lu, Xin _eauthor |
| 700 | 1 | 0 |
_a Wang, Guo-Chun _eauthor |
| 700 | 1 | 0 |
_a Peng, Qing-Lin _eauthor |
| 245 | 0 | 0 | _aAnti-Mi-2 antibodies characterize a distinct clinical subset of dermatomyositis with favourable prognosis |
| 260 | _c2020. | ||
| 500 | _a78 | ||
| 520 | _aBackground: Anti-Mi-2 antibody is a type of myositis-specific autoantibody found in idiopathic inflammatory myopathy patients. Objectives: To investigate the clinical features and long-term outcomes in anti-Mi-2-positive dermatomyositis (DM) patients. Materials and Methods: Serum anti-Mi-2β antibodies were detected in 357 DM patients by enzyme-linked immunosorbent assays, and possible associated clinical features were investigated based on cross-sectional and longitudinal studies. Results: Of the DM patients, 40/357 (11.2%) were positive for anti-Mi-2β antibodies and found to have a significantly higher frequency of V sign (72.5% vs 45.7%; p = 0.001), shawl sign (60.0% vs 35.6%; p = 0.003), and muscle weakness (77.5% vs 57.1%; p = 0.013), but a lower incidence of interstitial lung disease (ILD) (37.5% vs 60.9%; p = 0.005) and malignancy (0% vs 12.0%; p = 0.041) than anti-Mi-2β-negative patients. Anti-Mi-2β antibody levels positively correlated with disease activity. After a median follow-up period of 44 months, 97.0% of patients showed clinical remission. Twenty-six anti-Mi-2β-positive patients had a disease course longer than two years, and 16/26 (61.5%) were monocyclic without relapse. Moreover, five patients (15.1%) were drug-free with complete remission for more than three months. Kaplan-Meier survival curves showed that DM patients with positive anti-Mi-2β had a significantly lower mortality rate compared to anti-Mi-2β-negative patients (log-rank; p = 0.035). Interestingly, anti-Mi-2β antibodies did not disappear in all patients over time. Conclusion: Anti-Mi-2β antibodies were associated with a subgroup of DM with a low frequency of ILD and malignancy, good treatment response, and favourable outcome. Moreover, anti-Mi-2β levels correlated with disease activity. | ||
| 690 | _aMi-2 | ||
| 690 | _aclinical significance | ||
| 690 | _aoutcome | ||
| 690 | _adermatomyositis | ||
| 690 | _aantibody | ||
| 786 | 0 | _nEuropean Journal of Dermatology | 30 | 2 | 2020-03-01 | p. 151-158 | 1167-1122 | |
| 856 | 4 | 1 | _uhttps://shs.cairn.info/revue-european-journal-of-dermatology-2020-2-page-151?lang=en&redirect-ssocas=7080 |
| 999 |
_c602482 _d602482 |
||